From fixed cards to software-defined AST

Software-defined antimicrobial susceptibility testing

Combi-DX automates antimicrobial susceptibility testing (AST), one of the highest-volume tests in clinical microbiology, on a software-reconfigurable microfluidic cartridge. It replaces fixed test cards with software-defined testing, with a lower cost per case as the target.

In development · Not yet CE-IVD marked · Open to partner laboratories

A pipette loads a sample into a digital microfluidic cartridge seated in its instrument, with droplets visible on the electrode array
Digital microfluidic cartridge

News

· Antimicrobial resistance

World AMR Awareness Week: what the 2026 data say

World AMR Awareness Week runs from 18 to 24 November 2026 under the theme “One Health, one action: Prevent AMR now”. In 2023, one in six laboratory-confirmed bacterial infections worldwide was resistant to the antibiotics used to treat it, according to the World Health Organization.

In Switzerland, the Swiss Antibiotic Resistance Report 2026, published on 17 November, shows that E. coli causes around 75% of bladder infections in outpatient care, and that its resistance to extended-spectrum cephalosporins rose from 1% in 2004 to 14% in 2025. The report notes that knowledge of local resistance data is essential to guide empirical treatment.

These figures rest on susceptibility tests run in clinical laboratories. Combi-DX is developing a programmable cartridge on which, when the standard panel finds resistance, further antibiotics and dilutions are added during the run, once approved by an authorised professional. The platform is in development and not yet CE-IVD marked.

Combi-DX, implementation partner of ORION, an Innosuisse Flagship: illustration of a digital microfluidic cartridge

· Partnership

Combi-DX becomes an implementation partner of ORION, an Innosuisse Flagship

Combi-DX SA has taken over from Preciflex SA as an implementation partner of ORION, an Innosuisse Flagship. ORION brings together 24 partners to build an AI-driven microfactory for personalised cancer treatment. It was selected in Innosuisse's 2024 Flagship call on artificial intelligence in life sciences with a focus on human health.

Combi-DX brings digital microfluidics to the project: samples and reagents are handled as droplets on a cartridge, under software control, to miniaturise and automate laboratory tests. We thank Jérôme Charmet and HE-Arc Ingénierie for leading ORION and for their support during this transition.

Read the post on LinkedIn

Flat tariffs, rising testing costs

AST tells clinicians which antimicrobials will work against the microorganism isolated from a patient. It is routine work at scale, and its economics are unforgiving.

In Swiss outpatient care, a positive culture is paid once per sample, routine identification and AST included, whatever the number of isolates, and tariffs keep being cut; inpatient testing sits inside the hospital's case-based payment. Card-based analysers use one single-use card per isolate and panel: when the first panel does not answer the clinical question, the laboratory pays for another card while reimbursement does not move.

Laboratories weigh the full cost per completed case.

Our approach

Digital microfluidics turns the cartridge into a programmable test surface. Flexibility becomes margin.

01

Programmable cartridge

Droplets of sample and reagents move across an array of electrodes. Antibiotic panels and dilution series are defined in software. When the standard panel finds resistance, further antibiotics and dilutions are added during the run, once approved, without a new card.

02

Broth microdilution, phenotypic MIC

The cartridge applies the broth microdilution principle of EUCAST and CLSI in droplets and returns a phenotypic minimum inhibitory concentration (MIC) for each antibiotic, the result that guides targeted therapy.

03

Sized to the laboratory

A compact, modular instrument, designed to match the laboratory's peak workload. The target is a lower full cost per completed case and a better use of the fixed reimbursement.

Adaptive continuation, towards precision medicine for each patient and each infection. When a first result calls for further testing, the run continues with additional antibiotics and dilutions, each step approved by an authorised healthcare professional, instead of restarting the next day with a new card. This matters most in multidrug-resistant infections, where tests run in series.

One platform, three susceptibility tests

The same programmable platform serves antibiotics, phages and antifungals, a step towards precision medicine in infectious diseases.

Antibiotics · AST

Antimicrobial susceptibility testing

Broth microdilution and MIC for bacteria isolated in routine culture, the first application of the platform.

First validation series against the reference method completed with a Swiss clinical laboratory.

Phages · PST

Phage susceptibility testing

Which bacteriophages act against a patient's bacterial strain, for phage therapy research.

Research protocol under way with a Swiss university hospital.

Antifungals · AfST

Antifungal susceptibility testing

Susceptibility of fungal isolates to antifungal agents, on the same platform.

Collaboration in preparation with the University of Neuchâtel.

Synergy and antagonism between antimicrobials, relevant to multidrug-resistant infections, are a further research application of the platform. Combi-DX is an implementation partner of ORION, the Innosuisse Flagship led by HE-Arc on AI-driven personalised cancer treatment.

How it works

Three notions explain the Combi-DX platform.

Digital microfluidics (DMF)
Droplets sit on an array of electrodes covered by a thin insulating, water-repellent layer. Switching electrodes on and off changes how the surface wets, which moves, merges, splits and mixes the droplets. This principle is called electrowetting-on-dielectric (EWOD). The droplet path is a program, with no pumps or valves.
Broth microdilution
Microorganisms from a cultured isolate are exposed to a series of two-fold dilutions of each antimicrobial in liquid growth medium, then incubated. Growth, or its absence, is read at each concentration.
Minimum inhibitory concentration (MIC)
The lowest antimicrobial concentration that prevents visible growth. Compared with clinical breakpoints, such as those published by EUCAST in Europe and CLSI in the United States, the MIC classifies the isolate as susceptible, susceptible at increased exposure, or resistant.

Development stage

  1. Now

    Development and validation

    The cartridge, the instrument and the protocols are being developed and validated with Swiss clinical and academic partners: a Swiss clinical laboratory, a Swiss university hospital and the University of Neuchâtel.

  2. Next

    Research use

    Research-use systems in partner laboratories: antibiotics, phages and antifungals first, then dedicated clinical workflows.

  3. Target

    CE-IVD marking

    Routine AST and antifungal testing on cultured isolates under the EU In Vitro Diagnostic Regulation (IVDR), with a US FDA pathway to follow.

Work with us

We are open to discussing your needs now, while the platform is in development.

Laboratories

Partner laboratories

Clinical microbiology laboratories can take part in research-use evaluation and pilot studies of AST, PST or AfST on the Combi-DX platform, and help shape a test built around their workload.

Become a partner laboratory
Industry and research

R&D services

Feasibility studies, assay miniaturisation and custom development in digital microfluidics and microfluidics, for pharma, biotech, agri-science and academic teams.

See R&D services
Investors

Meet the team

Investors interested in Combi-DX can request a meeting with the CEO, in Neuchâtel or online.

Request a meeting

Company

Combi-DX SA is a Swiss medical technology company based in Neuchâtel. It is an independent company, incorporated in Neuchâtel on 18 June 2026, which is acquiring the digital microfluidics technology of Preciflex SA and builds on Preciflex's know-how in digital microfluidics and electrowetting. Its focus is in vitro diagnostics against antimicrobial resistance.

Legal name
Combi-DX SA (Combi-DX AG, Combi-DX Inc.)
Incorporated
18 June 2026, Neuchâtel, Switzerland
Registered office
Rue de Prébarreau 17, 2000 Neuchâtel
Company number
UID CHE-257.632.374

Team

Gregory Dourde

CEO and Chairman

Engineer from École des Ponts ParisTech, MBA from Collège des Ingénieurs. CEO of Preciflex SA and originator of the Combi-DX platform, with 25 years leading industrial and technology companies in Switzerland.

LinkedIn profile

Antony Croxatto, PhD, FAMH

Chief Scientific Advisor

Director of Microbiology at ADMed. Formerly head of serology and co-head of bacteriology, mycology and parasitology at CHUV, Lausanne University Hospital. PhD in microbiology and molecular biology, Umeå University.

LinkedIn profile

Daniel Nesta

CFO

Twenty years in finance leadership, including CFO of Geosatis and of Jean Singer & Cie, and fourteen years at Glenmark Pharmaceuticals as Head of Finance.

LinkedIn profile

Frequently asked questions

What does Combi-DX do?

Combi-DX SA is a Swiss medical technology company based in Neuchâtel. It automates antimicrobial susceptibility testing on a software-defined digital microfluidic cartridge, for antibiotics (AST), phages (PST) and antifungals (AfST), and offers R&D services in digital microfluidics and microfluidics.

What is software-defined AST?

Software-defined AST is antimicrobial susceptibility testing in which the antibiotic panel and the dilution series are set by software on a programmable cartridge. When the standard panel finds resistance, further antibiotics and dilutions can be added during the run, once approved, whereas card-based analysers need a new pre-filled card for each isolate and panel.

Why does the cost of AST matter to laboratories?

In Swiss outpatient care, a positive culture is paid once per sample, routine identification and AST included, whatever the number of isolates. With card-based analysers, every card is a cost the flat tariff has to absorb. Laboratories therefore weigh the full cost per completed case.

Which method does the Combi-DX platform use?

Broth microdilution on cultured isolates, applied in droplets on the cartridge following the principle of EUCAST and CLSI. The result is a phenotypic minimum inhibitory concentration (MIC) for each antimicrobial tested.

Which susceptibility tests can the platform run?

Three, on the same platform: antimicrobial susceptibility testing of bacteria (AST), validated against the reference method in a first series with a Swiss clinical laboratory; phage susceptibility testing (PST), in research use with a Swiss university hospital; and antifungal susceptibility testing (AfST), in preparation with the University of Neuchâtel.

Who does Combi-DX work with?

Combi-DX works with Swiss clinical and academic partners: phage susceptibility testing with a Swiss university hospital, and antifungal susceptibility testing, in preparation with the University of Neuchâtel. Combi-DX is an implementation partner of ORION, the Innosuisse Flagship led by HE-Arc on AI-driven personalised cancer treatment.

Can we work with Combi-DX today?

Yes. The Combi-DX platform is in development and not yet CE-IVD marked, so it cannot be used for clinical diagnosis today. We are open now to evaluation and pilot studies in research use with partner laboratories, to research collaborations, and to R&D projects in digital microfluidics.

Does Combi-DX offer R&D services?

Yes. Combi-DX offers feasibility studies, assay transfer and miniaturisation, and custom cartridge and protocol development in digital microfluidics and microfluidics. Typical fields are pharmaceutical and biotech laboratories (lab-on-a-chip assays), agri-science (for example soil microbiome studies) and academic research.

Who is behind Combi-DX?

Combi-DX is an independent company, incorporated in Neuchâtel, Switzerland, on 18 June 2026, which is acquiring the digital microfluidics technology of Preciflex SA. Gregory Dourde is CEO and Chairman, Antony Croxatto, PhD, FAMH, is Chief Scientific Advisor, and Daniel Nesta is CFO.

How can I contact Combi-DX?

By email at gregory@combi-dx.com. Laboratories, industry and research teams, and investors are welcome to get in touch.

Contact

Tell us about your laboratory, your project or your question.

Combi-DX SA
Rue de Prébarreau 17
2000 Neuchâtel, Switzerland